Testing lumenectomy samples for markers of non-vascular diseases
Lumenectomy material is tested to determine the presence or likelihood of a condition of a patient. The lumenectomy material is in the form of at least one continuous tissue strand collected in vivo from an inner surface of a body lumen of the patient. The presence of at least one marker of a disease is determined. The disease may be hypertension, hyperlipidemia, depression, obesity, metabolic syndrome, insulin resistance, kidney damage, or diabetes. The patient is identified as having or as likely to develop the disease if a marker of the disease is identified in the lumenectomy material of the patient.
1. A method for diagnosing a disease in a patient, the method comprising:
a) employing a catheter so as to collect lumenectomy material from an inner surface of a lumen of a body of said patient in a manner sufficient to ensure that the structure of the collected lumenectomy material retains the actual in vivo tissue structure, wherein the catheter is employed in such a manner that it planes across the inner surface of the body lumen and said planing action of the catheter results in the collection of the lumenectomy material; and further wherein the lumenectomy material comprises one continuous strand having:
a substantially consistent depth and width,
a length that ranges from about 2.0 mm to about 10 cm, and
a mass that ranges from 1 mg to about 2000 mg;
b) performing a test on said lumenectomy material to obtain test results, wherein the lumenectomy material retains the actual in vivo tissue structure throughout the test and wherein said test results in the identification of at least one marker of a disease selected from the group consisting of hypertension, hyperlipidemia, depression, obesity, metabolic syndrome, insulin resistance, kidney damage, and diabetes; and
c) diagnosing said patient for said disease based on said test results, wherein the disease is selected from the group consisting of hypertension, hyperlipidemia, depression, obesity, metabolic syndrome, insulin resistance, kidney damage, and diabetes.
2. The method according to claim 1 , wherein the test further results in the identification of an increased or decreased level of the marker as compared with a non-disease condition.
3. The method according to claim 1 , wherein said catheter comprises a housing and said housing comprises an aperture for collecting said lumenectomy material.
4. The method according to claim 3 , wherein the catheter further comprises a blade.
5. The method according to claim 4 , wherein the blade is translated via the aperture.
6. The method according to claim 5 , wherein said aperture is elongated and further comprises a cutting window.
7. The method according to claim 6 , wherein the lumenectomy material comprises a length that is longer than a length of the cutting window.
8. The method according to claim 7 , wherein the lumenectomy material is collected by translating the blade outside of the cutting window of the aperture.
9. The method according to claim 8 , wherein the blade and cutting window are advanced together so as to obtain the collection of the lumenectomy material.
10. The method according to claim 3 , wherein the planing action of the catheter results in the collection of said lumenectomy material within the aperture.
11. The method according to claim 5 , wherein translation of the blade results in the collection of the lumenectomy material.
12. The method according to claim 1 , wherein the length of the material ranges from about 2.0 mm to about 0.5 cm.
13. The method according to claim 1 , wherein the markers comprises one or more of a member selected from the group consisting of a DNA, a protein, and a RNA.
14. The method according to claim 1 , wherein the test further results in the identification of the presence or absence of the marker.
15. The method according to claim 1 , further comprising the collection of the lumenectomy material from a plurality of sites within said lumen of the patient's body.
16. The method according to claim 1 , further comprising the collection of the lumenectomy material from a plurality of lumens within the patient's body.
17. The method according to claim 1 , wherein the lumen comprises a diseased tissue.
18. The method according to claim 17 , wherein the diseased tissue comprises a plaque.
19. The method according to claim 18 , further comprising testing the patient's serum for the diseased marker.
20. The method according to claim 19 , wherein the plaque is enriched in disease markers in comparison to the patient's serum.
21. The method according to claim 1 , wherein the at least one marker of disease is a member selected from the group consisting of C-reactive protein, interleukin-6, intracellular adhesion molecule-1, angiotensin, vascular adhesion molecule-1, monocyte chemoattractant protein-1, aldosterone, atrial natriuretic factor, tissue factor pathway inhibitor, plasminogen activator inhibitor-1, triglycerides, apolipoprotein B, low density lipoprotein (LDL) particles, Remnant-like particles-cholesterol (RLP-C), and triglyceride-rich lipoproteins (TRL).
22. The method according to claim 1 , wherein said test comprises one or more of a member selected from the group consisting of genomic screening, DNA hybridization, RNA hybridization, gene expression analysis, PCR amplification, proteomic testing, drug efficacy screening, protein marker detection, DNA marker detection, RNA marker detection, histological testing, histopathology, cytopathology, cell and tissue type analysis, and a biopsy.
23. The method according to claim 1 , wherein the test comprises one or more of a member selected from the group consisting of enzyme histochemistry, immunohistology, immunocytochemistry, an immunoassay, an immunofluorescent assay, an immunoprecipitation assay, ELISA, flow cytometry, fluorescent activated cell sorting, radioimmunochemistry, electrophoresis, two-dimensional gel electrophoresis, a Western blot, protein sequencing, mass spectrometry, proteomic analysis, protein microarray analysis, a Nothern blot, an RNase protection assay, an in situ hybridization assay, DNA microarray testing, reverse transcription polymerase chain reaction PCR (RT-PCR), a Southern blot, DNA sequencing, PCR amplification, a single strand conformational polymorphism assay, a single strand polymorphism (SNP) assay, and a serial analysis of gene expression (SAGE) assay.
24. The method according to claim 1 , wherein said marker comprises one or more of a member selected from the group consisting of apoptotic markers, cell cycle proteins, transcriptional factors, proliferative markers, endothelial growth factors, adhesion molecules, cytokines, chemokines, chemokine receptors, inflammation markers, coagulation factors, fibrinolytic factors, oxidative stress related molecules, extracellular matrix molecules, interleukins, growth factors, glycoproteins, proteoglycans, cell-surface markers, serum markers, and immune factors.
25. The method according to claim 1 , wherein the markers comprises one or more of a member selected from the group consisting of C-reactive protein, interleukin-6, intracellular adhesion molecule-1, angiotensin II, aldosterone, atrial natriuretic factor, tissue factor pathway inhibitor, plasminogen activator inhibitor-1, triglycerides, apolipoprotein B, low density lipoprotein, Remnant-like particles, cholesterol, and triglyceride-rich lipoproteins.